Illumina Stock Crumbles As Earnings Outlook Completely Misses Forecasts

The company is a leader in using next-generation sequencing to "read" the human genome, a key technology as genetic and precision medicines gain steam. But for the year, Illumina expects to earn just 75 cents to 90 cents per share, minus some items. That widely missed forecasts for adjusted…#illumina #rbccapitalmarkets #charlesdadswell #novaseqx #ilmn #grail #elilillyhas #miratirockets #abevyofnewsincancer #trackandbuy

Source: Reuters: Health - August 9, 2023 Category: Consumer Health News Source Type: news